The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Abstract
BACKGROUND Ivonescimab is a bispecific antibody against programmed cell death protein 1 and vascular endothelial growth factor, yielding promising clinical outcomes for patients with advanced non-small cell lung cancer in early-phase studies. We compared the efficacy and safety of ivonescimab with pembrolizumab in patients with programmed cell death ligand-1 (PD-L1)-positive advanced non-small cell lung cancer. METHODS HARMONi-2 is a randomised, double-blind, phase 3 trial across 55 hospitals in China. Eligible patients were aged 18 years or older and had locally advanced or metastatic PD-L1-positive non-small cell lung cancer without sensitising epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations and an Eastern Cooperative Oncology Group performance-status of 0 or 1. Patients were randomly assigned (1:1) to receive 20 mg/kg ivonescimab or 200 mg pembrolizumab intravenously every 3 weeks. Randomisation was stratified by histology, clinical stage, and PD-L1 expression. The primary endpoint was progression-free survival (PFS) assessed by a masked independent radiographic review committee per RECIST v1.1 in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT05499390; recruitment is complete, with the trial ongoing and final analysis to be reported later. FINDINGS Between Nov 9, 2022, and Aug 26, 2023, 398 (45%) of 879 screened patients were randomly assigned to receive ivonescimab (n=198) or pembrolizumab (…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationThe biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 4,018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Self-citationMok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303
Self-citationNivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
Cited by
Hallmarks of cancer—Then and now, and beyond
Hanahan, D. (2026) · Cell · doi:10.1016/j.cell.2025.12.049 · Cited by 225
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Self-citationTumour and microenvironment crosstalk in NSCLC progression and response to therapy
Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 121
The next generation of immunotherapies for lung cancers
Zhao, S., Zhao, H., Yang, W., & Zhang, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01035-9 · Cited by 112
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
Zippelius, A., Tolaney, S. M., Tarantino, P., Balthasar, J. P., & Thurber, G. M. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00869-w · Cited by 100
Metadata
- Authors
- Xiong, A., Wang, L., Chen, J., Wu, L., Liu, B., Yao, J., Zhong, H., Li, J., Cheng, Y., Sun, Y., Ge, H., Yao, J., Shi, Q., Zhou, M., Chen, B., Han, Z., Wang, J., Bu, Q., Zhao, Y., Chen, J., Nie, L., Li, G., Li, X., Yu, X., Ji, Y., Sun, D., Ai, X., Chu, Q., Lin, Y., Hao, J., Huang, D., Zhou, C., Shan, J., Yang, H., Liu, X., Wang, J., Shang, Y., Mei, X., Yang, J., Lu, D., Hu, M., Wang, Z. M., Li, B., Xia, M., & Zhou, C.
- Affiliations
- Tongji University (CN)
- Hunan Cancer Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Shanghai Chest Hospital (CN)
- Gannan Medical University (CN)
- Jilin Province Tumor Hospital (CN)
- Shandong Tumor Hospital (CN)
- Guangzhou Medical University Cancer Hospital (CN)
- Chinese PLA General Hospital (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Henan Cancer Hospital (CN)
- Peking University First Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Zhejiang Cancer Hospital (CN)
- First Affiliated Hospital of Xinxiang Medical University (CN)
- Tianjin Chest Hospital (CN)
- First Affiliated Hospital of University of South China (CN)
- Tongji Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Army Medical University (CN)
- Changsha Central Hospital (CN)
- Third Xiangya Hospital (CN)
- Affiliated Hospital of Hebei University (CN)
- Anhui Provincial Hospital (CN)
- Corresponding author
- Zhou, Caicun
- ORCID
- Wang, Lei
- Chen, Jianhua
- Wu, Lin
- Yao, Jun
- Zhong, Hua
- Li, Jie
- Cheng, Ying
- Ge, Hui
- Shi, Qin
- Zhou, Ming
- Chen, Bolin
- Han, Zhengxiang
- Bu, Qing
- Zhao, Yanqiu
- Chen, Junqiang
- Li, Gaofeng
- Li, Xingya
- Sun, Daqiang
- Chu, Qian
- Hao, Jiqing
- Huang, Dingzhi
- Zhou, Chengzhi
- Shan, Jinlu
- Mei, Xiaodong
- Yang, Jie
- Wang, Zhongmin Maxwell
- Li, Baiyong
- Xia, Michelle
- Zhou, Caicun
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2025-03
- Volume
- 405
- Issue
- 10481
- Pages
- 839-849
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4408177149
- Cited by
- 173
- References
- 22
- Citations by year
- 2026: 97 · 2025: 76
- FWCI
- 71.64
- Type
- journal article
- Language
- en
- Update notices
- erratum (2025-11-01)
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- ivonescimab, pembrolizumab, PD-L1-positive non-small cell lung cancer, bispecific antibodies, vascular endothelial growth factor, PD-1 inhibitors, progression-free survival, immune checkpoint inhibitors, metastatic lung cancer, China, subgroup analysis, safety and tolerability, adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Progression-Free Survival, Immune Checkpoint Inhibitors, Adult, Aged, Carcinoma, Non-Small-Cell Lung, China, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Antibodies, Bispecific, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. https://app.cochat.ai/papers/10.1016/s0140-6736(24)02722-3
- The paper
- Xiong, A., Wang, L., Chen, J., Wu, L., Liu, B., Yao, J., Zhong, H., Li, J., Cheng, Y., Sun, Y., Ge, H., Yao, J., Shi, Q., Zhou, M., Chen, B., Han, Z., Wang, J., Bu, Q., Zhao, Y., . . . Zhou, C. (2025). Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. The Lancet. https://doi.org/10.1016/s0140-6736(24)02722-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.